Actavis debuts new formulations of Fioricet

30 July 2013

US generics major Actavis (NYSE: ACT) has launched new formulations of Fioricet (butalbital, acetaminophen and caffeine capsules, USP) and Fioricet with Codeine (butalbital, acetaminophen, caffeine and codeine phosphate, USP) containing a lower dose of acetaminophen, designed to provide a safer treatment option for patients suffering from tension (or muscle contraction) headaches.

Actavis’ new formulations of Fioricet and Fioricet with Codeine reduce the amount of acetaminophen in the products from 325mg to 300mg, following a Food and Drug Administration guideline that recommended manufacturers limit the dose of acetaminophen in all prescription drug products. Neither the total number of pills that may be prescribed, nor the time interval at which they may be prescribed, will change with the new formulations.

Risk of acute liver failure

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK